BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G. Sacubitril/valsartan in COVID-19 patients: the need for trials. Eur Heart J Cardiovasc Pharmacother 2020;6:253-4. [PMID: 32369103 DOI: 10.1093/ehjcvp/pvaa044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Vitiello A, La Porta R, Ferrara F. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses 2021;147:110486. [PMID: 33460992 DOI: 10.1016/j.mehy.2021.110486] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
2 Rex DAB, Arun Kumar ST, Modi PK, Keshava Prasad TS. Broadening COVID-19 Interventions to Drug Innovation: Neprilysin Pathway as a Friend, Foe, or Promising Molecular Target? OMICS 2021;25:408-16. [PMID: 34191617 DOI: 10.1089/omi.2021.0080] [Reference Citation Analysis]
3 Haji Abdolvahab M, Moradi-Kalbolandi S, Zarei M, Bose D, Majidzadeh-A K, Farahmand L. Potential role of interferons in treating COVID-19 patients. Int Immunopharmacol 2021;90:107171. [PMID: 33221168 DOI: 10.1016/j.intimp.2020.107171] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
4 Haybar H, Maniati M, Saki N, Zayeri ZD. COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies. Mol Biol Rep 2021;48:2917-28. [PMID: 33837899 DOI: 10.1007/s11033-021-06333-w] [Reference Citation Analysis]
5 Vitiello A, Ferrara F. Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. Wien Klin Wochenschr 2021. [PMID: 33877436 DOI: 10.1007/s00508-021-01855-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Sankhe R, Rathi E, Manandhar S, Kumar A, Pai SRK, Kini SG, Kishore A. Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study. J Mol Struct 2021;1224:129073. [PMID: 32834116 DOI: 10.1016/j.molstruc.2020.129073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 Karamyan VT. Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19? Physiol Rep 2021;9:e14796. [PMID: 33687143 DOI: 10.14814/phy2.14796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mahajan K, Chand Negi P, Ganju N, Sondhi S, Gaur N, Somendra R. Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts. Int J Hypertens 2020;2020:1025913. [PMID: 33145103 DOI: 10.1155/2020/1025913] [Reference Citation Analysis]
9 Di Micco P, Di Micco G, Russo V, Poggiano MR, Salzano C, Bosevski M, Imparato M, Fontanella L, Fontanella A. Blood Targets of Adjuvant Drugs Against COVID19. J Blood Med 2020;11:237-41. [PMID: 32694923 DOI: 10.2147/JBM.S256121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]